Perception Neuroscience Announces Appointments of Maju Mathews, MD, as Chief Medical Officer and Cedric Burg, PhD as Senior Vice President, Clinical Operations.
New York, NY
May 5, 2022
Perception Neuroscience, Inc is pleased to announce the appointments of Maju Mathews, MD, as Chief Medical Officer and Cedric Burg, PhD as Senior Vice President, Clinical Operations.
Maju Mathews, is a Board-Certified Psychiatrist with over 13 years of neuroscience drug development experience focused on psychiatric drugs. He joins us from Janssen Pharmaceuticals where he most recently held the position of Senior Global Medical Affairs Leader for Neuropsychiatry.
During his time at Janssen, Maju worked on eight different compounds across multiple psychiatric conditions, most recently contributing to the development and approval of esketamine (SPRAVATO®) for Treatment Resistant Depression and Suicidality. Prior to joining Janssen, he held roles of increasing responsibilities at Forest Labs and Indivior, overseeing the development of programs in major depression, generalized anxiety disorder, bipolar mania, bipolar depression, schizophrenia, substance misuse and a number of pediatric programs. Before entering the pharmaceutical industry, Maju was a Senior Medical Officer Reviewer at the U.S. Food and Drug Administration (FDA) for three years, where he was responsible for multiple NDA, IND and safety reviews.
Maju brings extensive knowhow to the Perception Neuroscience team with his broad experience in research, medical affairs, regulatory and market access, and as a practicing clinician. He will be responsible for all aspects of the clinical, medical and regulatory strategy and clinical development of the company's assets. Maju continues to practice medicine – focusing on caring for those living with mood disorders and/or ADD.
Cedric Burg graduated from American University in Washington D.C. with a bachelor’s degree in Biology and went on to obtain a PhD in Pharmacology from the University of Nantes, France.
With more than 20 years’ experience in the clinical development field, he has held various senior positions in Pharma and Biotech on both sides of the Atlantic. Cedric’s most recent role was as Senior Vice President and Head of Clinical Operations at BioXcel where he was responsible for Clinical Operations as well as overall project management of the company’s drug development programs for immuno-oncology and psychiatry.
Cedric’s career started in Spain in clinical research at Phidea and he brings a breadth of experience in data management, regulatory affairs, CRO management and quality assurance from roles at Teva, Bristol Myers Squibb.
We are thrilled to welcome them to the team and are excited by the extensive knowledge and energy they bring to our company.
About Perception Neuroscience, Inc
Perception Neuroscience is a New York City- based biopharmaceutical company committed to developing therapies for neuropsychiatric diseases. Perception's mission is to provide substantially more effective treatment solutions to serious psychiatric disorders. The company is a majority-owned subsidiary of atai Life Sciences.